A role for surgery in primary pancreatic B-cell lymphoma: a case report by Liakakos, Theodore et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Journal of Medical Case Reports
Open Access Case report
A role for surgery in primary pancreatic B-cell lymphoma: a case 
report
Theodore Liakakos1, Evangelos P Misiakos*1, Dimitrios Tsapralis1, 
Irene Nikolaou2, Gabriel Karatzas1 and Anastasios Macheras1
Address: 1Third Department of Surgery, University of Athens School of Medicine, Attikon University Hospital, Rimini 1 Street, Chaidari, Athens, 
Greece and 2Department of Pathology, University of Athens School of Medicine, Attikon University Hospital, Rimini 1 Street, Chaidari, Athens, 
Greece
Email: Theodore Liakakos - theodlia@otenet.gr; Evangelos P Misiakos* - misiakos@med.uoa.gr; Dimitrios Tsapralis - tsapralisd@yahoo.gr; 
Irene Nikolaou - lektcsurg@attikonhospital.gr; Gabriel Karatzas - gchirklin@med.uoa.gr; Anastasios Macheras - anmach@med.uoa.gr
* Corresponding author    
Abstract
Introduction: Primary pancreatic lymphoma is a very rare but manageable malignant tumour
which may be clinically confused as a pancreatic carcinoma. This case report demonstrates the
value of surgical resection in the management of pancreatic lymphoma.
Case presentation: We report a case of a 65-year-old man who was admitted with obstructive
jaundice, vague upper abdominal pain and weight loss. Ultrasonography and computed tomography
showed a mass at the head of the pancreas which was compressing the bile duct. The patient
underwent pancreaticoduodenectomy. Histopathologic and immunohistochemical assessment of
the pancreatic lesion established the diagnosis of a diffuse, extranodal, high-grade B-cell non-
Hodgkin's lymphoma. Several doses of chemotherapy were administered postoperatively and at
present the disease remains in remission.
Conclusion: The favourable outcome for this patient and a thorough review of the literature
underline the important role that operative resection may have in the management of at least the
early stage of primary pancreatic lymphoma.
Introduction
Non-Hodgkin's lymphoma (NHL) most frequently arises
from the lymphatic system, with the gastrointestinal (GI)
tract representing the most commonly involved extran-
odal site, accounting for half of such cases. In Western
series, GI lymphoma occurs principally in the stomach,
followed by the small bowel and the colon [1]. Primary
involvement of the pancreas in lymphoma is rare, repre-
senting a small fraction (less than 1 to 2%) of all pancre-
atic malignancies [2]. To distinguish primary pancreatic
lymphoma (PPL) from secondary involvement of the pan-
creas by NHL, Behrns' diagnostic criteria include: a pre-
dominant pancreatic mass with gross involvement of only
the peripancreatic lymph nodes; no hepatic or splenic
involvement; no palpable superficial lymphadenopathy;
no enlargement of the mediastinal lymph nodes on chest
radiograph; and a normal leukocyte count [3].
Current standard management for PPL has relied mainly
on the use of various chemotherapeutic protocols, such as
the commonly used regimen of cyclophosphamide, doxo-
rubicin, vincristine and dexamethazone (CHOP). The role
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of surgery in the management of pancreatic lymphoma
has been limited to obtaining diagnostic tissue samples or
to bypassing biliary obstruction [4]. More recently, less
invasive techniques, such as image-guided percutaneous
biopsy, have successfully provided a tissue diagnosis in
more than 80% of patients [5].
Although initial results with chemotherapy were encour-
aging, recent studies with longer follow up of patients
with NHL treated with standard chemotherapy with or
without radiotherapy have demonstrated higher recur-
rence rates, particularly for patients with abdominal lym-
phomas [6]. Given the modest results of standard
chemotherapy, the known benefits of surgical resection in
the prognosis of other GI lymphomas [7], and recent
improvements in clinical outcome after radical pancreatic
surgery, the role of surgical resection in the treatment of
pancreatic NHL is being reassessed [2].
Here we present the case of a patient initially managed as
suffering from adenocarcinoma of the pancreas, who ulti-
mately proved to have PPL. The combined treatment of
radical surgical resection and chemotherapy resulted in a
good clinical outcome.
Case presentation
A 65-year-old man with a 4-week history of mild epigas-
tric pain radiating to the back (exacerbated after meals),
progressive obstructive jaundice, anorexia and weight loss
of 3 kg was admitted to our Department of Surgery in
November 2005. There was no history of a change in
bowel habit, melena, haematochezia, pancreatitis, liver or
gallbladder disease. The patient had undergone open
repair of an abdominal aortic aneurysm 5 years previously
and he was a heavy smoker (40 pack-years) and had a
high alcohol intake (300 ml/day).
Upon admission, the patient was icteric, afebrile and had
normal vital signs. Physical examination revealed normal
bowel sounds, deep jaundice and mild tenderness in the
epigastrium and right upper quadrant, without evidence
of peripheral lymphadenopathy, palpable mass or hepat-
osplenomegaly. The patient had an unremarkable haema-
tological profile, but the liver function tests were
abnormal: aspartate transaminase (AST) 253 IU/l, alanine
transaminase (ALT) 393 IU/l, total bilirubin 7.9 mg/ml,
direct bilirubin 6.41 mg/ml, alkaline phosphatase 236 U/
l and gamma glutamyl transpeptidase (GGT) 462 U/l.
Both serum carcinoembryonic antigen titre and serum car-
bohydrate antigen titre were normal.
The patient underwent ultrasonography of the liver, bil-
iary tract and pancreas, which revealed a hypoechoic mass
at the head of the pancreas. Further assessment of this
finding with helical, contrast-enhanced abdominal com-
puted tomography (CT) demonstrated the presence of a
large, hypodense, non-homogeneous lesion at the head of
the pancreas, with a maximal diameter of 5 cm, without
dilatation of the main pancreatic duct (Figure 1). Limited
lymphadenopathy was also detected in the peripancreatic
and the para-aortic regions. The tumour was in contact
with the superior mesenteric vein (SMV) without signs of
infiltration or encasement of the vein or of the superior
mesenteric artery (SMA). The patient also underwent
upper GI endoscopy, which revealed mild gastritis in the
gastric antrum without evidence of malignancy in the
stomach or duodenum. A CT-guided fine needle aspira-
tion (FNA) biopsy was not diagnostic, and the patient was
scheduled for exploratory laparotomy.
At surgery, a large mass at the pancreatic head was found,
which could be easily separated from the contiguous vas-
cular structures with blunt dissection. Interestingly, the
tumour did not seem macroscopically to invade the sur-
rounding viscera. A pancreaticoduodenectomy (Whipple
procedure) was performed. Histologic evaluation of the
surgical specimen revealed extensive involvement of the
pancreas by a diffuse, extranodal, high grade, large cell,
NHL (centroblastic lymphoma). A neoplastic population,
consisting of large non-cleaved lymphoid cells with nucle-
oli, was seen to surround pancreatic ducts; no lymphoep-
ithelial lesions were present (Figure 2). A few small
reactive T lymphocytes CD3+ and CD45R0+ (Dako, Glos-
rtup, Denmark) were observed. Immunohistochemical
assessment of the neoplastic cells revealed B lymphoid
phenotypes CD20+ (Dako) (Figure 3) and CD10+ (Cell
Contrast-enhanced helical CT scan Figure 1
Contrast-enhanced helical CT scan. This scan demonstrates 
the heterogeneous enhancement of a large tumour of the 
head of the pancreas, in contact with the superior 
mesenteric vein (SMV), without signs of infiltration or 
encasement of the vein, or the superior mesenteric artery 
(SMA).Journal of Medical Case Reports 2008, 2:167 http://www.jmedicalcasereports.com/content/2/1/167
Page 3 of 6
(page number not for citation purposes)
Marque Corporation, USA), and the cells were negative
for CD3, CD45R0, CD30, CD15, ALK (anaplastic lym-
phoma kinase), EMA (epithelial membrane antigen)
(Dako) and EBN-A2 (Epstein-Barr virus nuclear antigen 2)
(Dako). Mitotic activity was very high (Ki67 (Dako) >
80%) (Fig. 4). The tumour was classified as stage IIE
according to the Ann Arbor classification [8,9]. The resec-
tion margins were free of disease. However, all adjacent
lymph nodes in the gastric or peripancreatic region were
infiltrated by the tumour.
In the immediate postoperative course, the patient had
several episodes of bilious vomiting shortly after food
intake, attributed to oedema of the gastrojejunostomy,
which gradually resolved. He also developed a pancreatic
fistula which completely resolved after 5 weeks without
affecting the patient's nutritional status or electrolyte bal-
ance.
After surgery the patient underwent four chemotherapeu-
tic sessions consisting of cyclophosphamide, novantrone,
vincristine and prednisone, all administered at 3-week
intervals. Twenty-one months after surgery the patient was
alive and in a good clinical condition.
Discussion
PPL is a very rare neoplasm that may be confused with
adenocarcinoma, the most common neoplasm of the
pancreas. An extensive review of the international litera-
ture has revealed a total of 162 adult patients with biopsy-
proven NHL primarily involving the pancreas (Table 1)
[2,3,10-17]. The clinical manifestation of PPL is non-spe-
cific and differentiation from pancreatic adenocarcinoma
on a clinical basis is difficult. Only in cases where a patient
presents with abdominal pain and a palpable mass with-
out jaundice is the clinical suspicion of pancreatic lym-
phoma, over adenocarcinoma, enhanced.
There are some biochemical markers which, in conjunc-
tion with suspicious clinical manifestations, may help
focus the physician's attention on the possibility of a pan-
creatic lymphoma. More specifically, lactate dehydroge-
nase (LDH) and β2 microglobulin are considered to be
tumour markers in lymphoproliferative disorders and
have an important positive prognostic value. Serum car-
bohydrate antigen 19-9 (CA 19-9) level in patients with
PPL is usually not elevated. This is in contrast with pancre
High mitotic activity highlighted by Ki67 expression (Ki67 ×  200) Figure 4
High mitotic activity highlighted by Ki67 expression (Ki67 × 
200).
Neoplastic lymphoid population surrounding pancreatic duct  with no evidence of lymphoepithelial lesions (H/E × 200) Figure 2
Neoplastic lymphoid population surrounding pancreatic duct 
with no evidence of lymphoepithelial lesions (H/E × 200).
CD20 positivity of neoplastic lymphoid cells (CD20 × 200) Figure 3
CD20 positivity of neoplastic lymphoid cells (CD20 × 200).Journal of Medical Case Reports 2008, 2:167 http://www.jmedicalcasereports.com/content/2/1/167
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Table 1: Literature review of primary pancreatic lymphoma: patients' characteristics, pathologic types, treatment and outcome
First author Year Number (n) Pathology Operation Chemotherapy Radiotherapy Outcome Response
Feather 1951 1 DLBCL Total 
Pancreatectomy
None None 16 months – NED CR
Acherman 1976 3 DLBCL None CHOP Yes 12 months – NED CR
Boddie 1980 2 DLBCL
Freed 1983 1 NR Distal 
Pancreatectomy
None None 12 months – NED CR
Teefy 1986 2 DLBCL (1) FLCL (1) None Yes Yes 12 months – Death PR
Hart 1987 14 Histiocytic (9) Poorly 
diff lymphocytic (2) 
Well diff lymphocytic 
(1) T-cell (1) 
Undifferentiated(1)
Distal 
Pancreatectomy (1)
CHOP (14) 1 of 14 NR (1 with resection) 
Death (7) at 3 to 108 
months)
NR
Webb 1988 9 DLBCL (6) Follicular 
mixed (2) Small 
cleaved (1)
Distal 
Pancreatectomy (1)
MACOP-B (8) 
CAMEL (1)
None 95 months-NED (1) 21 
months-NED (8)
CR
Mansour 1989 12 NR Distal 
Pancreatectomy(1)
CHOP (11) 5 of 9 Death (5) in 2 to 11 
months, Recurrence (2) in 
3 and 48 months
PR
Cappell 1989 1 DLBCL
Tuchek 1993 7 NR None CHOP (1) CVP (1) 
CAMEL (1)
NR Death (4) Alive (3) at 60, 
72, 96 months
CR
Borrowdale 1994 1 NR Whipple Yes None Death in 12 months CR
Behrns 1994 12 DLBCL (7) Small 
cleaved (2) Mixed (3)
Whipple (1) Bypass 
(4)
CHOP (4) 4 of 12 Death in 38 months at 
most
PR
Fidias 1995 3 DLBCL None CHOP None Death (1) Recurrence (1) 
NED in 36 months(1)
CR (2) PR (1)
Tanaka 1996 1 DLBCL (1) Whipple CHOP NR NED in 36 months CR
Ezzat 1996 5 DLBCL (5) Whipple (1) CHOP (4) CHOP-
Ble (1)
NR NED in 21 to 84 months 
(4)
PR
Rumstadt 1997 2 DLBCL (2) Whipple (2) CHOP (1) None NED in 29 months CR
Bouvet 1997 11 DLBCL (10) Mixed 
follicular (1)
Whipple (1) Distal 
Pancreaticoduo-
denectomy (2)
CHOP-Bleo 7of 11 Death (3) Recurrence (2) 
NED (6)
CR
James 1997 2 DLBCL (1) None CHOP (1) 
PACEBO + CHOP 
(1)
1 of 2 NED in 24 months PR
Koniaris 2000 8 DLBCL (7) Nixed 
follicular (1)
Whipple (3) CHOP (6) 
MACOP-B
None Death (2) NED (3, 
resection)
CR
Islam 2001 1 DLBCL Bypass, biopsy CHOP None NED in 18 months CR
Nishimura 2001 19 DLBCL (15) T-cell 
(4)
Pancreatectomy(10
)
CHOP (5) 
Mitomycin Tegafur 
(1) Unspecified 
chemo (1)
NR 1-year actuarial survival B-
cell: 51.9% T-cell: 0%
PR
Boni 2002 1 DLBCL (1) Laparoscopy-
biopsy
Chemo (1) None NED in 9 months CR
Hauksson 2002 1 DLBCL PTC stenting 
biopsy
Chemo NR NR NR
Volmar 2004 14 DLBCL (6) follicular 
(4) Suggestive of 
lymphoma (3) B 
lymphoma (1)
No Yes NR Death (3) Alive (11) in a 
mean 11.8- month 
followup
2 PR 11 CR
Nayer 200410 8 DLBCL (4) High-
grade B-cell (1) Low 
grade B (2) 
Suspicious (1)
None Chemo (4) Chemo 
and auto SCT (2) 
Nr (2)
3 of 8 6 alive at 2 to 6 months PR
Pezzilli 2004 1 T-cell lymphoma None Chemo (1) None Death (1) NR
Arcari 2005 5 DLBCL (3) 
Lymphoplasmacytic 
(2)
Pancreatectomy (2) CVP/CHOP(3) 
CHOP(1) CVP(1)
2 of 5 Death (3) Alive 2, (1, 
resection)
PR
Grimison 2005 4 DLBCL (3) Follicular 
(1)
None CHOP(2) 
Rituximab-
CHOP(1) CVP(1)
4 Death 132 months Alive 3 
at 15, 25, 64 months
PR
Ji 2005 1 DLBCL (1) Whipple (1) NR NR NR NR
Savopoulos 2005 1 ALCL (1) Biopsy None None Died 2nd postoperative day -
Kang 2006 1 Non-Hodgkin's 
lymphoma
Biopsy NR NR NR NR
Lin 2006 6 DLBCL (6) Whipple (2) 
Pancreatectomy (1) 
Biliary 
decompression (1)
Chemo (6) γ-radiotherapy (1) Death (3) at 2, 37, 49 
months NED in 21 months 
(1)
PR
Battula 2006 1 DLBCL (1) Whipple (1) CHOP (1) NR NR NR
Liakakos 2007 1 DLBCL (1) Whipple (1) Cyclophosphamide 
Novantrone 
Vincristine 
Prednisone
No Alive (2 years) PR
DLBCL, diffuse large B-cell lymphoma; FLCL, follicular large cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; PACEBO, prednisolone, 
hydroxydaunorubicine, cyclophosphamide, etoposide, bleomycin, vincristine; CAMEL, cyclophosphamide, adriamycin, vincristine, prednisone; CVP, cyclophosphamide, vincristine, 
prednisone; SCT, stem cell transplantation; NED, no evidence of disease; NR, not reported; CR, complete response; PR, partial responseJournal of Medical Case Reports 2008, 2:167 http://www.jmedicalcasereports.com/content/2/1/167
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atic adenocarcinoma, in which almost 80% of cases have
a high CA19-9 level [11].
Pancreatic lymphoma, like most extralymphatic lympho-
mas, is predominantly of intermediate or high-grade his-
tology, with diffuse large B-cell lymphoma being the
predominant type [12]. Less than 20% of reported cases
demonstrate low-grade histology. The majority of pancre-
atic lymphomas reported to date in the literature have
been classified as of B-cell type, but several cases of T-cell
lymphomas have also been described [13].
CT is the most common imaging technique used in the
detection and characterization of PPL. On CT, two differ-
ent morphologic patterns of pancreatic involvement are
seen; one is a localized, well-circumscribed tumour with
diffuse enlargement infiltrating most of the pancreatic
gland. This pattern may mimic the imaging findings of
acute pancreatitis with gland enlargement and irregular
infiltration of the peripancreatic fat [14]. The well-circum-
scribed tumoural form can be easily misinterpreted as a
ductal adenocarcinoma, especially in patients with dilata-
tion or encasement of the pancreatic and common bile
ducts [15]. In contrast, the combination of a bulky, local-
ized tumour in the pancreatic head without significant
dilatation of the main pancreatic duct, as seen in our case,
strengthens a diagnosis of pancreatic lymphoma over ade-
nocarcinoma. Furthermore, if enlarged lymph nodes are
encountered below the level of the renal veins, in associa-
tion with a large pancreatic tumour, virtual exclusion of
adenocarcinoma is possible [14].
Contrast-enhanced CT also offers certain criteria to define
the resectability of pancreatic tumours: the absence of
extrapancreatic disease; preservation of the fat plane
between the tumour and the confluence of superior
mesenteric and portal vein (SMPV); and absence of
tumour involving or encasing the SMA, coeliac or hepatic
arteries [15]. Therefore, one may rely on the CT findings
without the need for additional imaging studies in order
to evaluate the resectability of a pancreatic head tumour.
Although certain serum abnormalities and CT changes are
suggestive of lymphoma, tissue examination is essential
for diagnosis. Patients presenting with advanced disease
may be diagnosed by peripheral lymph node FNA, core or
open biopsy [2,16]. However, there are cases in which the
performance of explorative laparotomy becomes manda-
tory due to the inability of the aforementioned diagnostic
modalities to differentiate between pancreatic adenocarci-
noma and some other types of pancreatic malignancy
[4,11].
At present, the standard protocols for management of
pancreatic lymphomas include a number of chemother-
apy regimens [10]. The most commonly used regimen is
the first-generation therapy CHOP [2], but a range of sec-
ond- and third-generation regimens are also used.
Expected outcomes for all NHL treatments, based on
multi-institutional studies using CHOP or an equivalent
chemotherapy, with or without radiotherapy, regardless
of location, are a complete response rate of approximately
50%, and a partial response rate of approximately 30%.
Overall, a 3-year disease-free survival rate of 46% has been
reported after such therapies [6].
The observed moderate long-term survival rates for pan-
creatic NHL with chemotherapy and radiotherapy alone,
and the improvements in morbidity and mortality associ-
ated with pancreatic surgery, call for a re-evaluation of
therapeutic strategies for NHL of the pancreas [17]. A ret-
rospective analysis and a comparison of 15 surgically
treated patients with PPL (treated between 1951 and 2000
in several centres) with non-operatively treated stage I or
II pancreatic NHL patients (encountered over a similar
period) by Koniaris et al. [2] demonstrated markedly
improved complete remission and cure rates in the surgi-
cally treated group. Detailed comparison between the sur-
gically treated and non-surgically treated groups reveals
that age, histologic subtypes and male to female ratio were
similar in the two groups. Tumour size was clearly larger
in the non-operated group and in many cases patients
treated conservatively had unresectable disease. However,
the successfully resected group represented a dramatic
complete response rate of 100% and long-term survival
rate of 94%. These data suggest that for surgically resecta-
ble stage I or II pancreatic NHL, resection should be an
option in the multimodal therapeutic regimen [11]. To
the potential role of surgery in the treatment of pancreatic
NHL should be added its well-established place in the
management of lymphoma involving other GI organ sys-
tems, such as gastric and small bowel lymphomas [7].
Conclusion
When a patient with a pancreatic mass is encountered,
preoperative contrast-enhanced CT or magnetic resonance
imaging should be obtained. Only in cases in which the
resectability of a pancreatic head mass is regarded as
impossible, according to the above criteria, should the
performance of a definite tissue diagnosis be contem-
plated. This is achieved with the aid of percutaneous FNA
and flow cytometry analysis. If a mass located in the head
of the pancreas is regarded as potentially resectable, we
advocate explorative laparotomy of the patient. If the
intraoperative findings confirm the feasibility of resection
of the tumour, pancreaticoduodenectomy is advocated,
provided that the surgery is performed by surgeons well-
practised with the nuances required for safe pancreatic
resection, especially in the case of PPLs, which alsoPublish with BioMed Central    and   every 
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respond well to treatment with chemotherapy and radio-
therapy alone.
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